<DOC>
	<DOCNO>NCT02456935</DOCNO>
	<brief_summary>The purpose study demonstrate efficacy CJ-12420 , daily ( QD ) , compare esomeprazole patient erosive esophagitis classify Los Angeles ( LA ) classification grade A D Week 8</brief_summary>
	<brief_title>Study Evaluate Safety Efficacy CJ-12420 Patients With Erosive Esophagitis</brief_title>
	<detailed_description>This double blind , randomize , active control , phase 3 study . Subjects randomly assign one two treatment group ( CJ-12420 100 mg esomeprazole 40 mg ) . All subject ask take two tablet time day throughout study , also subject ask record daytime nighttime symptom subject diary daily basis .</detailed_description>
	<mesh_term>Esophagitis</mesh_term>
	<mesh_term>Esomeprazole</mesh_term>
	<criteria>1 . Subjects age 20 70 year 2 . Subjects experience heartburn regurgitation within 7 day visit 1 . Entry study also require patient experience least mild upper gastrointestinal symptom least 2 days/week least moderate upper gastrointestinal symptom least 1 day/week 3 . Endoscopically confirm erosive esophagitis define LA Classification Grading System ( AD ) within 14 day prior randomization 4 . Subjects able understand follow instruction willing participate throughout entire study 5 . Subjects voluntarily sign write informed consent form 6 . Subjects agree use medically acceptable contraceptive period study . 1 . Subjects undergo EGD 2 . Subjects esophageal stenosis , ulcer stenosis , gastroesophageal varix , Barrett 's esophagus , active gastric ulcer , gastrointestinal bleeding malignant tumor confirm EGD 3 . Subjects warn symptom malignant gastrointestinal tract odynophagia , severe dysphagia , bleeding , weight loss , anemia , bloody stool 4 . Subjects eosinophilic esophagitis 5 . Subjects diagnose primary esophageal motility disorder , IBS , IBD , etc . suspect IBS last 3 month 6 . Subjects history gastric acid suppression surgery upper gastrointestinal , esophageal surgery 7 . Pregnant lactate woman 8 . Subjects history clinically significant hepatic , renal , cardiovascular , respiratory , endocrine CNS system disorder 9 . Subjects history hypersensitivity active ingredient excipients study drug , etc . 10 . Subjects participate clinical trial within 4 week prior randomization</criteria>
	<gender>All</gender>
	<minimum_age>20 Years</minimum_age>
	<maximum_age>70 Years</maximum_age>
	<verification_date>December 2016</verification_date>
</DOC>